Rituximab: Uses in Dermatology

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

Rituximab is an anti-CD20 monoclonal antibody with considerable potential in dermatology due to an increase in off-label indications. Chronic graft-versus-host disease and pemphigus vulgaris are two of the most promising indications for off-label use of rituximab. It is a generally safe alternative that should be considered when traditional therapy with corticosteroids or immunosuppressants has failed or caused significant intolerance. Currently, rituximab is only FDA-approved for treatment of follicular and diffuse large B-cell non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia, granulomatosis with polyangiitis (formerly Wegener's granulomatosis) and microscopic polyangiitis. Herein, off-label uses of rituximab and its efficacy in the treatment of cutaneous diseases are reviewed.

Original languageEnglish (US)
Pages (from-to)5-7
Number of pages3
JournalSkin therapy letter
Volume21
Issue number5
StatePublished - Sep 1 2016

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Rituximab: Uses in Dermatology'. Together they form a unique fingerprint.

Cite this